These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24338508)

  • 21. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
    Nasti G; Piccirillo MC; Izzo F; Ottaiano A; Albino V; Delrio P; Romano C; Giordano P; Lastoria S; Caracò C; de Lutio di Castelguidone E; Palaia R; Daniele G; Aloj L; Romano G; Iaffaioli RV
    Br J Cancer; 2013 Apr; 108(8):1566-70. PubMed ID: 23558891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
    Nagaoka T; Osumi H; Ueno T; Ooki A; Wakatsuki T; Nakayama I; Ogura M; Takahari D; Chin K; Matsueda K; Yamaguchi K; Shinozaki E
    Int J Clin Oncol; 2023 Sep; 28(9):1191-1199. PubMed ID: 37349660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
    Viganò L; Capussotti L; Barroso E; Nuzzo G; Laurent C; Ijzermans JN; Gigot JF; Figueras J; Gruenberger T; Mirza DF; Elias D; Poston G; Letoublon C; Isoniemi H; Herrera J; Sousa FC; Pardo F; Lucidi V; Popescu I; Adam R
    Ann Surg Oncol; 2012 Sep; 19(9):2786-96. PubMed ID: 22622469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
    Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
    Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
    Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
    Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
    J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
    Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
    Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
    Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases.
    Zorzi D; Chun YS; Madoff DC; Abdalla EK; Vauthey JN
    Ann Surg Oncol; 2008 Oct; 15(10):2765-72. PubMed ID: 18636296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
    Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.